Severe Hepatic Sinusoidal Obstruction Syndrome in a Child Receiving Vincristine, Actinomycin-D, and Cyclophosphamide for Rhabdomyosarcoma: Successful Treatment with Defibrotide.
- Author:
Aery CHOI
1
;
Young Kyung KANG
;
Sewon LIM
;
Dong Ho KIM
;
Jung Sub LIM
;
Jun Ah LEE
Author Information
- Publication Type:Case Report
- Keywords: Hepatic veno-occlusive disease; Rhabdomyosarcoma; Defibrotide
- MeSH: Child*; Cyclophosphamide*; Drug Therapy; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease*; Humans; Liver; Rhabdomyosarcoma*; Vincristine*
- From:Cancer Research and Treatment 2016;48(4):1443-1447
- CountryRepublic of Korea
- Language:English
- Abstract: Hepatic sinusoidal obstruction syndrome (SOS) is a life-threatening syndrome that generally occurs as a complication after hematopoietic stem cell transplantation or, less commonly, after conventional chemotherapy. Regarding SOS in rhabdomyosarcoma patients who received conventional chemotherapy, the doses of chemotherapeutic agents are associated with the development of SOS. Several cases of SOS in rhabdomyosarcoma patients after receiving chemotherapy with escalated doses of cyclophosphamide have been reported. Here, we report on a 9-year-old female with rhabdomyosarcoma who developed severe SOS after receiving chemotherapy consisting of vincristine, actinomycin-D, and a moderate dose of cyclophosphamide. She was treated successfully with defibrotide without sequelae to the liver.
